Anastasia Bukhman appointed to the T1D Fund Board of Directors

Anastasia Bukhman, Co-Founder of the Bukhman Foundation, has been appointed to the Board of Directors of The T1D Fund, an impact investment fund focused on accelerating the development of therapies to treat, prevent, and ultimately cure type 1 diabetes.

The appointment reflects a shared commitment to advancing innovative, disease-modifying therapies and strengthening international collaboration across the T1D ecosystem.

Elizabeth Mily, CEO of the T1D Fund, noted that Anastasia brings “philanthropic leadership and valuable strategic perspective,” adding that her support for T1D innovation and international collaboration will contribute to the Fund’s efforts to expand its network and advance promising therapies for people at risk of, newly diagnosed with, and living with type 1 diabetes.

In 2025, the Bukhman Foundation announced a $12 million donation to the T1D Fund to accelerate cure-oriented therapies and support the next wave of innovation in T1D.

This commitment, alongside Anastasia’s role on the Fund’s Board, reflects the Foundation’s broader approach to supporting projects and people that expand understanding of the disease and open new therapeutic pathways, with the aim of contributing to solutions that are both life-changing and enduring.

"The T1D Fund represents a uniquely powerful model for translating scientific promise into meaningful progress for patients and shares the Bukhman Foundation’s commitment to the T1D community. I am honored to join the Board and support its mission to bring together capital, expertise, and partnerships to accelerate breakthroughs that can change lives.”

Anastasia Bukhman, Co-Founder - Bukhman Foundation.

"We are thrilled to add Anastasia to our board as she will add a new dimension of experience and thinking while also helping to expand our geographical reach in what is clearly a global disease. Anastasia’s track record in philanthropy and focus on T1D brings us a partner who we believe will only help enhance our efforts, attract new capital and companies, and turbo charge our momentum.”

Jay Eastman, Chair of the T1D Fund Board of Directors

About the T1D Fund
Launched in 2016, the T1D Fund is the first scaled venture fund established to catalyse the development of cure-oriented therapies for type 1 diabetes. The Fund co-invests alongside venture capital and biopharmaceutical partners to support early-stage companies developing disease-modifying therapies and potential cures.

A core element of the Fund’s mission is to advance promising therapies efficiently through development and toward regulatory approval. It works in close partnership with Breakthrough T1D and The Leona M. and Harry B. Helmsley Charitable Trust, two leading global organisations dedicated to supporting the T1D community and advancing research and innovation.

Led by an experienced team of healthcare and investment professionals, the Fund draws on an extensive network spanning research, clinical, regulatory, and medical affairs. Capitalised through philanthropic funding, it invests in biotechnology companies and recycles returns into new investments, extending the long-term impact of donor contributions.